Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gemcitabine + S-1 and SBRT for borderline resectable pancreatic cancer
ChiCTR1800017746Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: R0 resection rate. Started Mar 2017; status: recruiting.
02
Drugs
gemcitabinetegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1800017746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017746.